Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS

Inclusion Criteria

• •Patient with a clinical suspicion for a new diagnosis of AML or MDS for whom the diagnostic molecular testing via the hematologic molecular algorithm (HMA) at BJH is requested or planned to be requested.
• •Adult patients 18 years or older.
• •Ability to understand and willingness to sign an IRB approved written informed consent document.
• •Treating physician at Washington University School of Medicine who directs therapy for individuals with hematologic malignancies.
• •Able and willing to complete standardized questionnaires about usability, and stakeholder perceptions of ChromoSeq during the ChromoSeq implementation process.